Do nicotinic receptor ligands have the potential to revolutionize Parkinsons disease?
The Parkinson’s Institute has claimed the use of nicotine for the treatment of levodopa-induced dyskinesia. The potential of nicotinic receptor ligands as treatments of Parkinson’s disease itself has been recognized for a number of years, however use as an adjunct to levodopa represents a new advance. • Full and up to date pipeline UpdatesPlus continuously tracks development activity behind all known nicotinic agonists, antagonists and modulators including: MEM 63908/R4996, ABT-107, TC-5619, EVP-6124, AZD-0328, SSR-180711, GTS-21,MEM 3454 (R3487), Varenicline (Chantix/Champix), TC-6499, ABT-560, AZD3480 (TC-1734), TC-5214, Ispronicline, ABT-894, ABT-089 Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and a
